This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
This is an overview of the field of immuno-oncology and the various immuno-oncology classes.
Immuno-oncology is one of the most promising and fastest growing areas of cancer research, as well as one of the most active areas in terms of licensing deals and acquisitions. To be able to compete successfully and competitively in this market, this report is vital to add to your arsenal.
Included in this report?
Three fully transcribed key opinion leader interviews
Coverage of the key immuno-oncology targets include key clinical trial results and a summary of deals related to that class
10-year sales forecasts are included for Yervoy, Opdivo, Keytruda, MEDI4736, and RG7446
Development focus map shows which targets are being investigated by each of the 63 companies with immuno-oncology drugs in development